Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2008

View Archived Issues

Nanoscalic silver less toxic than silver sulfadiazine in treating skin infections

Novel agents for cardiovascular disorders reported in recent patents

Sanofi-aventis issues 2007 overview

Recent Kyorin patent describes new treatment option for transplant rejection

New antipsychotic and anxiolytic agents described in recent patent literature

Targeting midkine useful in multiple sclerosis model

NSC-668814 effective against cisplatin-resistant ovarian cancer in vitro

CHP-HER2 vaccine elicits HER2-specific immune responses in advanced cancer

Urigen reports phase II study results with URG-101 in painful bladder syndrome

In vivo results demonstrate good safety profile for Upstream's leishmaniasis drug candidates

FDA grants approval to Zymenex's IND application for phase II clinical trial of Metazym

DSMB recommends continuation of Sangart's two phase III clinical trials of Hemospan

Oxigene plans to file an IND for Zybrestat based on positive results in primates

Creagene reports positive results from preclinical toxicity tests for CreaVax-HCC injection

Horizontal gene transfer makes it possible to produce a novel class of antibiotics

FDA issues nonapprovable letter for Luitpold's NDA for Injectafer in iron deficiency anemia

AstraZeneca completes enrollment in ZODIAC and ZEAL phase III studies of Zactima

ArQule starts enrollment in phase I/II ARQ-197 non-small cell lung cancer trial

Raven to advance development of its new IND candidate RAV-18

Vertex and Tibotec commence phase III ADVANCE study with telaprevir in HCV

BioInvent enters agreement with Bayer HealthCare for human monoclonal antibodies

Recordati completes mutual recognition process in Europe for lercanidipine/enalapril

AVI BioPharma acquires Ercole Biotech

Unigene reports results from phase I/II clinical study of oral calcitonin

Celsion initiates screening of patients in phase II study of ThermoDox in HCC

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...